CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at three upcoming investor conferences:
UBS Biopharma Conference 2023
5:00 pm ET on Wednesday, November 8, 2023.
6th Annual Evercore ISI HealthCONx Conference
3:00 pm ET on Wednesday, Nov 29, 2023.
Piper Sandler 35th Annual Healthcare Conference
1:00 pm ET on Thursday, November 30, 2023.
The fireside chats will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a liver-directed oral therapy that is designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$407.09 |
| Daily Change: | 15.43 3.94 |
| Daily Volume: | 591,681 |
| Market Cap: | US$9.070B |
August 05, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
